MD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

485.47M

-3.36%

0.538

+5.5%

473.79M

+3.37%

0.385

+16.53%

485.63M

+3.58%

0.568

+7.2%

Estimates Revision

The market is revising Upward the revenue expectations for Pediatrix Medical Group, Inc. (MD) for FY2025, with the revenue forecasts being adjusted by 1.1% over the past three months. During the same period, the stock price has changed by 37.95%.

Revenue Estimates for FY2025

Revise Upward

+1.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+16.26%

In Past 3 Month

Stock Price

Go Up

+37.95%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast MD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MD is 21.33 USD with a low forecast of 17.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

2 Hold

0 Sell

Moderate Buy

Current: 22.320

Low

17.00

Averages

21.33

High

24.00

Current: 22.320

Low

17.00

Averages

21.33

High

24.00

Truist

David MacDonald

Hold

maintain

$17 -> $24

2025-11-10

Reason

Truist

David MacDonald

Price Target

$17 -> $24

2025-11-10

maintain

Hold

Reason

Truist analyst David MacDonald raised the firm's price target on Pediatrix Medical to $24 from $17 and keeps a Hold rating on the shares. The firm is updating its model to reflect the company's Q3 earnings beat and guidance raise, the analyst tells investors in a research note.

UBS

Neutral

maintain

$23

2025-11-05

Reason

UBS

Price Target

$23

2025-11-05

maintain

Neutral

Reason

UBS raised the firm's price target on Pediatrix Medical to $23 from $16.50 and keeps a Neutral rating on the shares. Pricing growth drove a strong Q3, and UBS expects stable hospital administrative fees in 2026, the analyst tells investors in a research note.

Truist

David MacDonald

Hold

maintain

$16 -> $17

2025-10-14

Reason

Truist

David MacDonald

Price Target

$16 -> $17

2025-10-14

maintain

Hold

Reason

Truist analyst David MacDonald raised the firm's price target on Pediatrix Medical to $17 from $16 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results in Healthcare Service. The firm is "broadly bullish" on the industry as it expects ongoing strength in core demand drivers and continues to like the long-term positioning of covered names within their sector verticals, coupled with improved visibility around the regulatory environment, the analyst tells investors in a research note. Strong free cash flows and attractive financial flexibility across the bulk of the sector underpins the ongoing growth investment, Truist notes, adding that it sees a "brisk opportunity" to deploy capital to further augment core growth and drive M&A.

UBS

AJ Rice

Neutral

maintain

$16

2025-08-14

Reason

UBS

AJ Rice

Price Target

$16

2025-08-14

maintain

Neutral

Reason

UBS analyst AJ Rice raised the firm's price target on Pediatrix Medical to $16.50 from $16 and keeps a Neutral rating on the shares.

UBS

AJ Rice

Neutral

downgrade

$16

2025-05-12

Reason

UBS

AJ Rice

Price Target

$16

2025-05-12

downgrade

Neutral

Reason

UBS analyst AJ Rice lowered the firm's price target on Pediatrix Medical to $16 from $18.50 and keeps a Neutral rating on the shares. 2025 is starting out strong for Pediatrix, and capital deployment remains a focus, the analyst tells investors in a research note.

Truist Securities

David Macdonald

Hold

Maintains

$18 → $16

2025-04-11

Reason

Truist Securities

David Macdonald

Price Target

$18 → $16

2025-04-11

Maintains

Hold

Reason

Truist analyst David MacDonald lowered the firm's price target on Pediatrix Medical to $16 from $18 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Pediatrix Medical Group Inc (MD.N) is 10.47, compared to its 5-year average forward P/E of 11.05. For a more detailed relative valuation and DCF analysis to assess Pediatrix Medical Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

11.05

Current PE

10.47

Overvalued PE

15.19

Undervalued PE

6.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

8.69

Current EV/EBITDA

7.42

Overvalued EV/EBITDA

11.11

Undervalued EV/EBITDA

6.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.76

Current PS

0.98

Overvalued PS

1.08

Undervalued PS

0.44

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MD News & Events

Events Timeline

No data

News

4.5

12-12NASDAQ.COM

Mid-Cap ETFs Experience Strong Momentum: Is Further Growth on the Horizon?

4.0

12-12NASDAQ.COM

Daily Upgrade Report for Validea's Joel Greenblatt Strategy - December 12, 2025

3.0

11-24NASDAQ.COM

Top Value Stocks to Consider Purchasing on November 24

People Also Watch

Frequently Asked Questions

What is Pediatrix Medical Group Inc (MD) stock price today?

The current price of MD is 22.32 USD — it has decreased -1.63 % in the last trading day.

What is Pediatrix Medical Group Inc (MD)'s business?

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

What is the price predicton of MD Stock?

What is Pediatrix Medical Group Inc (MD)'s revenue for the last quarter?

Pediatrix Medical Group Inc revenue for the last quarter amounts to 492.88M USD, decreased -3.58 % YoY.

What is Pediatrix Medical Group Inc (MD)'s earnings per share (EPS) for the last quarter?

Pediatrix Medical Group Inc. EPS for the last quarter amounts to 0.84 USD, increased 265.22 % YoY.

What changes have occurred in the market's expectations for Pediatrix Medical Group Inc (MD)'s fundamentals?

How many employees does Pediatrix Medical Group Inc (MD). have?

Pediatrix Medical Group Inc (MD) has 2150 emplpoyees as of December 17 2025.

What is Pediatrix Medical Group Inc (MD) market cap?

Today MD has the market capitalization of 1.92B USD.